Laurus labs has signed an MOA with IIT Kanpur (IITK) to bring novel gene therapy assets to market. As per MOA, Laurus labs will in-license few gene therapy assets and will provide research grant for advancing these products through the pre-clinical development. Laurus will also provide funding for the clinical trials and will launch these products in India and emerging markets. Additionally, Laurus labs will establish a GMP facility at the Techno Park facility of IITK.
Department of Biological Sciences and Bioengineering (BSBE) at IIT Kanpur has been working on gene therapy for the last few years and have developed few gene therapy assets along with technology for novel Adeno Associated Virus (AAV) vectors. They have filed IPs around these products and few additional patent applications will be filed in due course.
This partnership allows Laurus Labs to strengthen its presence in the promising Cell and Gene Therapy (CGT) space and allows it to become a leader in this space. These therapies are not available in India and emerging markets and this collaboration will help us in bringing these novel therapies to Indian patients at an affordable pricing. Additionally, this allows Laurus labs to offer CDMO services to cell and gene therapy companies.
Commenting on this development, CEO of Laurus Labs Dr. Satyanarayana Chava said,
